INS and fatty liver disease: Glycemic control should be optimized using agents with hepatic benefits, particularly GLP-1 receptor agonists and SGLT2 inhibitors, which not only improve insulin sensitivity but also promote weight loss and reduce hepatic steatosis [78,79].